J Thorac Oncol:17年来,NSCLC病理报告的准确性和完整性随时间的变化

2021-07-21 MedSci原创 MedSci原创

通过合理设计的干预措施,可以有效识别、量化和提高NSCLC病理报告的质量

完整准确的病理报告对于手术的管理和预后预测均至关重要。本研究旨在评估不同类型医院的三种干预措施对手术切除后非小细胞肺癌 (NSCLC) 的病理报告的影响。

Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the United States

研究人员评估了2004年-2020年在美国4个州的11个医疗机构中接受NSCLC根治性手术切除的患者的病理报告在三种质量提高干预实施前后的完整性和准确性:教育(反馈提高意识)、天气报告和淋巴结标本采集试剂盒。研究人员在6个患者队列中对比了将病理报告的比例与术后管理最重要的六个项目(标本类型、肿瘤大小、组织学、病理 (p) T分类、pN分类、切缘状态)。

六项关键项目的完整性随时间的变化

在干预后时代,报告所有关键项目的完整性概率是干预前时代的8倍(OR 8.3; 95%CI 6.7-10.2;p<0.0001)。与干预前时代相比,干预后时代pT和pN分类的准确率分别增加了6倍和8倍(pT OR:5.7;pN OR:8.0;p<0.0001)。在干预组中,接受了三种干预措施的患者报告的所有六个关键项目、准确的pT分类和准确的pN分类的几率最高。

pT和pN分类的准确性随时间的变化

综上所述,该研究结果表明,通过合理设计的干预措施,可以有效识别、量化和提高NSCLC病理报告的质量

原始出处:

Smeltzer Matthew P,Lee Yu-Sheng,Faris Nicholas R et al. Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the United States.[J] .J Thorac Oncol, 2021, https://doi.org/10.1016/j.jtho.2021.06.027

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006747, encodeId=94812006e47df, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Mon Jul 26 01:47:48 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906005, encodeId=4762190600562, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Dec 13 19:47:48 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057075, encodeId=c822205e075ee, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Sep 15 06:47:48 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866163, encodeId=7448186616372, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 10 21:47:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037853, encodeId=7511103e853b7, content=JTO上有很多不错的好文章,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038367, encodeId=c276103836ecd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039842, encodeId=9add1039842d0, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2006747, encodeId=94812006e47df, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Mon Jul 26 01:47:48 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906005, encodeId=4762190600562, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Dec 13 19:47:48 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057075, encodeId=c822205e075ee, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Sep 15 06:47:48 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866163, encodeId=7448186616372, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 10 21:47:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037853, encodeId=7511103e853b7, content=JTO上有很多不错的好文章,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038367, encodeId=c276103836ecd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039842, encodeId=9add1039842d0, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2006747, encodeId=94812006e47df, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Mon Jul 26 01:47:48 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906005, encodeId=4762190600562, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Dec 13 19:47:48 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057075, encodeId=c822205e075ee, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Sep 15 06:47:48 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866163, encodeId=7448186616372, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 10 21:47:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037853, encodeId=7511103e853b7, content=JTO上有很多不错的好文章,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038367, encodeId=c276103836ecd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039842, encodeId=9add1039842d0, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-09-15 yyj062
  4. [GetPortalCommentsPageByObjectIdResponse(id=2006747, encodeId=94812006e47df, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Mon Jul 26 01:47:48 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906005, encodeId=4762190600562, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Dec 13 19:47:48 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057075, encodeId=c822205e075ee, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Sep 15 06:47:48 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866163, encodeId=7448186616372, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 10 21:47:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037853, encodeId=7511103e853b7, content=JTO上有很多不错的好文章,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038367, encodeId=c276103836ecd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039842, encodeId=9add1039842d0, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-09-10 minlingfeng
  5. [GetPortalCommentsPageByObjectIdResponse(id=2006747, encodeId=94812006e47df, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Mon Jul 26 01:47:48 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906005, encodeId=4762190600562, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Dec 13 19:47:48 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057075, encodeId=c822205e075ee, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Sep 15 06:47:48 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866163, encodeId=7448186616372, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 10 21:47:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037853, encodeId=7511103e853b7, content=JTO上有很多不错的好文章,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038367, encodeId=c276103836ecd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039842, encodeId=9add1039842d0, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-07-21 肿瘤克星

    JTO上有很多不错的好文章,谢谢梅斯及时上新

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2006747, encodeId=94812006e47df, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Mon Jul 26 01:47:48 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906005, encodeId=4762190600562, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Dec 13 19:47:48 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057075, encodeId=c822205e075ee, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Sep 15 06:47:48 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866163, encodeId=7448186616372, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 10 21:47:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037853, encodeId=7511103e853b7, content=JTO上有很多不错的好文章,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038367, encodeId=c276103836ecd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039842, encodeId=9add1039842d0, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-07-21 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2006747, encodeId=94812006e47df, content=<a href='/topic/show?id=99ff45888bc' target=_blank style='color:#2F92EE;'>#完整性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45888, encryptionId=99ff45888bc, topicName=完整性)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Mon Jul 26 01:47:48 CST 2021, time=2021-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1906005, encodeId=4762190600562, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Mon Dec 13 19:47:48 CST 2021, time=2021-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057075, encodeId=c822205e075ee, content=<a href='/topic/show?id=a19b1e4042f' target=_blank style='color:#2F92EE;'>#THORAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17404, encryptionId=a19b1e4042f, topicName=THORAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=052a130, createdName=yyj062, createdTime=Wed Sep 15 06:47:48 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866163, encodeId=7448186616372, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 10 21:47:48 CST 2021, time=2021-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037853, encodeId=7511103e853b7, content=JTO上有很多不错的好文章,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038367, encodeId=c276103836ecd, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039842, encodeId=9add1039842d0, content=NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿肿, createdTime=Wed Jul 21 17:47:48 CST 2021, time=2021-07-21, status=1, ipAttribution=)]
    2021-07-21 肿肿

    NSCLC下一步突破在于新靶点了,靶向治疗和免疫治疗基本见顶了,再有新的就需要新机制了

    0

相关资讯

Lancet respirat:同济大学3期临床试验揭示埃克替尼在EGFR突变型晚期NSCLC中的疗效

与化疗相比,埃克替尼显著提高了NSCLC患者的无病生存期,并且具有更好的耐受性

J Clin Oncol:晚期NSCLC患者围手术期加用度伐单抗显著提高了1年EFS率

在IIIA(N2)期非小细胞肺癌患者的新辅助化疗方案中加入围手术期度伐单抗治疗安全且高效

Lancet oncol:Pralsetinib有望用于治疗RET融合阳性的NSCLC

对于携带RET融合阳性的NSCLC患者,普拉替尼是一种新型的、耐受良好的、有希望的口服治疗选择

Lancet Oncol:杜鲁伐单抗联合立体定向放疗明显改善早期NSCLC患者预后

杜鲁伐单抗新辅助治疗联合立体定向放疗的耐受性良好,安全性高,且可提高早期NSCLC患者的主要病理缓解率

NMPA批准阿斯利康的小细胞肺癌免疫疗法Imfinzi

7月19日,国家药品监督管理局 (NMPA) 的批准了阿斯利康研发用于治疗广泛期小细胞肺癌的Imfinzi (durvalumab) 免疫疗法。

Eur J Cancer:不符合临床研究标准的实体恶性肿瘤患者一线免疫治疗的疗效评估

该研究表明真实世界中大约三分之一患者不符合免疫治疗临床试验的入组标准,虽然不符合研究标准的患者一线应用免疫治疗能够得到约三分之一的应答,但是总体疗效差于符合研究标准的患者。